Adverse event monitoring of the human papillomavirus vaccines in Scotland
- 7 April 2016
- journal article
- Published by Wiley in Internal Medicine Journal
- Vol. 46 (4), 452-457
- https://doi.org/10.1111/imj.13005
Abstract
Human papillomavirus (HPV) vaccines are currently utilised globally in national immunisation programmes. While evidence from clinical trials and epidemiological studies suggest that the HPV vaccines are both effective and safe, concerns about the safety of the vaccine and scientifically unproven associations with severe adverse events following immunisation have led to dramatic decreases in vaccine uptake in Japan and acceptance issues in other countries.In Scotland, we utilised hospital admissions data to assess the impact of the HPV immunisation programme on the incidence of 60 diagnoses between 2004 and 2014 in both girls and boys; with boys acting as a comparator group. Tabular and graphical outputs of the number of admissions, the incidence and the incidence ratio of 59 diagnoses were created to assess trends before and after the introduction of the HPV vaccine. Data linkage was utilised to further investigate the increase in Bell's palsy diagnoses.54 diagnoses showed no change in incidence following the introduction of the national immunisation programme and while small increases in incidence were observed for Bell's palsy, coeliac disease, ovarian dysfunction, juvenile onset of type 1 diabetes, demyelinating disease and juvenile rheumatoid arthritis, none were statistically significant.Consistent with previous evidence, we present disaggregate data that reiterates the safety of both HPV vaccines.Keywords
This publication has 23 references indexed in Scilit:
- HPV vaccination crisis in JapanThe Lancet, 2015
- Active monitoring of potential adverse immunisation events with hospital admission data and linked analysis in ScotlandThe Lancet, 2014
- Reduction of low- and high-grade cervical abnormalities associated with high uptake of the HPV bivalent vaccine in ScotlandBritish Journal of Cancer, 2014
- Recent progress and concerns regarding the Japanese immunization program: Addressing the “vaccine gap”Vaccine, 2014
- Introduction and sustained high coverage of the HPV bivalent vaccine leads to a reduction in prevalence of HPV 16/18 and closely related HPV typesBritish Journal of Cancer, 2014
- Pooled analysis of large and long‐term safety data from the human papillomavirus‐16/18‐AS04‐adjuvanted vaccine clinical trial programmePharmacoepidemiology and Drug Safety, 2014
- Human Papillomavirus Vaccine Introduction – The First Five YearsVaccine, 2012
- Current controversies in the USA regarding vaccine safetyExpert Review of Vaccines, 2010
- Comparison of the immunogenicity and safety ofCervarix™ andGardasil®human papillomavirus (HPV) cervical cancer vaccines in healthy women aged 18–45 yearsHuman Vaccines, 2009
- Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind, randomised controlled trialThe Lancet, 2007